[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-31442":3,"doc-seo-31442":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},31442,2336464648322,"Aria","https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488",8,"Research & Report","Formation and Evaluation of Doxorubicin and Cromoglycate Metal–Organic Framework for Anti-Cancer Activity","Copper-based metal–organic frameworks (Cu-MOFs) were formulated to incorporate cromolyn as an organic linker, aiming to improve structural stability, drug-delivery performance, and anti-cancer efficacy, with a focus on breast cancer. Two formulations were synthesized: Cu-MOFs-BDC-DOX using terephthalic acid and Cu-MOFs-CROMO-DOX using cromolyn. Morphology and integrity were verified by SEM/TEM, FTIR, XRD, and TGA, followed by encapsulation and 48 h release studies at pH 7.4, and in vitro assays with MDA-MB-231 cells.","cbCaiu3r9htuMft4","https://ap.wps.com/l/cbCaiu3r9htuMft4","pdf",10169587,1,13,"English","en","# Introduction\n# Materials & Methods\n# Results\n## Encapsulation and drug release\n## In vitro anticancer activity\n# Conclusions","[{\"question\":\"What is the main goal of the study on Cu-MOFs?\",\"answer\":\"To develop copper-based metal–organic frameworks that use cromolyn as a linker to enhance stability, drug-delivery efficiency, and therapeutic potential for breast cancer treatment.\"},{\"question\":\"How were the two Cu-MOF formulations designed and compared?\",\"answer\":\"Cu-MOFs-BDC-DOX was synthesized using terephthalic acid, while Cu-MOFs-CROMO-DOX used cromolyn as the linker; both were characterized and then tested for encapsulation, release, and anti-cancer effects.\"},{\"question\":\"Which formulation showed stronger cytotoxicity against breast cancer cells, and what was the IC50?\",\"answer\":\"Cu-MOFs-CROMO-DOX showed superior cytotoxicity, with an IC50 of 0.88 ± 0.07 µM versus 7.1 ± 0.11 µM for Cu-MOFs-BDC-DOX.\"}]",1779483706,33,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":84,"head_meta":86,"extra_data":88,"updated_unix":25},105,"formation-and-evaluation-of-doxorubicin-and-cromoglycate-metalorganic-framework-for-anti-cancer-activity","",{"@graph":34,"@context":83},[35,52,66],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,49],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":48},"https://docshare.wps.com/document/research-report/",3,{"item":50,"name":13,"@type":41,"position":51},"https://docshare.wps.com/document/formation-and-evaluation-of-doxorubicin-and-cromoglycate-metalorganic-framework-for-anti-cancer-activity/31442/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":39,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-05-22",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79],{"name":70,"@type":71,"acceptedAnswer":72},"What is the main goal of the study on Cu-MOFs?","Question",{"text":73,"@type":74},"To develop copper-based metal–organic frameworks that use cromolyn as a linker to enhance stability, drug-delivery efficiency, and therapeutic potential for breast cancer treatment.","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"How were the two Cu-MOF formulations designed and compared?",{"text":78,"@type":74},"Cu-MOFs-BDC-DOX was synthesized using terephthalic acid, while Cu-MOFs-CROMO-DOX used cromolyn as the linker; both were characterized and then tested for encapsulation, release, and anti-cancer effects.",{"name":80,"@type":71,"acceptedAnswer":81},"Which formulation showed stronger cytotoxicity against breast cancer cells, and what was the IC50?",{"text":82,"@type":74},"Cu-MOFs-CROMO-DOX showed superior cytotoxicity, with an IC50 of 0.88 ± 0.07 µM versus 7.1 ± 0.11 µM for Cu-MOFs-BDC-DOX.","https://schema.org",{"og:url":50,"og:type":85,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":87,"canonical":50},"index,follow",{"doc_id":7,"site_id":30}]